Eagle’s Eye View: Your Weekly CV Update From ACC.org (Week of Dec. 22)

This week’s View looks at differences in results of the REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) and STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) trials and if they can be explained by the active and comparator oils on lipid traits and C-reactive protein (CRP). Dr. Eagle also examines whether traditional CV risk factors are associated with incident ASCVD among those with absent coronary calcium. And finally, Dr. Eagle looks at driving restrictions in those receiving a secondary prevention ICD.